Facility of ESBATech
  Zurich

Alcon as the world leader in ophthalmology welcomes ESBATech as its new entity responsible for advancing biologics, in particular antibody fragments for the treatment of ocular diseases.

ESBATech will remain in Zurich – Schlieren to become the Center of Excellence of Alcon in the field of biologics.

With the support of Alcon, ESBATech has a unique opportunity to develop new antibody fragment-based medicines for ocular diseases. ESBATech will be responsible for activities from discovery up to clinical proof-of-concept, while Alcon will be leading further clinical development and apply its global marketing and sales expertise and network to bring new medicines on the market. Both companies share the vision to develop new treatments to help patients better see.

For further information on Alcon, please visit www.alcon.com